Studie CONTESSA_ODO-TE-B301

CONTESSA_ODO-TE-B301

A Multinational, Multicenter, Randomized, Phase 3 Study of
Tesetaxel plus a Reduced Dose of Capecitabine versus
Capecitabine Alone in Patients with HER2 Negative, Hormone
Receptor Positive, Locally Advanced or Metastatic Breast
Cancer Previously Treated with a Taxane

Frauenklinik Frauenklinik Ismaninger Str. 22 81675 München Germany

III

Rekrutierung aktiv

Unbekannt / Unbekannt

Chemo,Zielgerichtet - Therapieart: palliativ